8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 10, 2026·SEC
Material company update
Mar 4, 2026·SEC
Vir Biotechnology, Inc.(VIR)Earnings, Financials & Key Ratios
VIR•NASDAQ
$10.29
$1.66B mkt cap·Price updated May 6, 2026
AboutVir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.Show more
- Revenue$69M-7.6%
- EBITDA-$456M+20.3%
- Net Income-$438M+16.1%
- EPS (Diluted)-3.16+17.5%
- Gross Margin82.92%+115.2%
- EBITDA Margin-665.65%+13.7%
- Operating Margin-682.68%+13.7%
- Net Margin-638.87%+9.2%
- ROE-45.73%-20.0%
- ROIC-40.27%-14.2%
- Debt/Equity0.24+187.0%
VIR Key Insights
Vir Biotechnology, Inc. (VIR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 91 (top 9%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
VIR Price & Volume
Vir Biotechnology, Inc. (VIR) stock price & volume — 10-year historical chart
Loading chart...
VIR Growth Metrics
Vir Biotechnology, Inc. (VIR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years0.39%
3 Years-65.12%
TTM-7.61%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.09%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM17.28%
Return on Capital
10 Years-26.52%
5 Years-7.65%
3 Years-38.51%
Last Year-42.76%
VIR Recent Earnings
Vir Biotechnology, Inc. (VIR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 4/12 qtrs (33%)
Q1 2026Latest
Feb 23, 2026EPS
$0.31
Est $0.42
+26.2%
Revenue
$64M
Est $20M
+221.9%
Q4 2025
Nov 5, 2025EPS
$1.17
Est $0.70
-67.1%
Revenue
$240,000
Est $20M
-98.8%
Q3 2025
Aug 6, 2025EPS
$0.80
Est $0.72
-11.1%
Revenue
$1M
Est $3M
-55.4%
Q2 2025
May 7, 2025EPS
$0.88
Est $0.83
-6.0%
Revenue
$2M
Est $9M
-79.1%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 23, 2026 | $0.31vs $0.42+26.2% | $64Mvs $20M+221.9% |
| Q4 2025 | Nov 5, 2025 | $1.17vs $0.70-67.1% | $240,000vs $20M-98.8% |
| Q3 2025 | Aug 6, 2025 | $0.80vs $0.72-11.1% | $1Mvs $3M-55.4% |
| Q2 2025 | May 7, 2025 | $0.88vs $0.83-6.0% | $2Mvs $9M-79.1% |
Based on last 12 quarters of dataView full earnings history →
VIR Peer Comparison
Vir Biotechnology, Inc. (VIR) competitors in Vaccines and Infectious Disease — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 MNKD | 1.1B | 3.56 | 178 | 22.23% | -6.63% | |||
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 ADMA | 2.46B | 10.08 | 16.80 | 19.63% | 28.8% | 34.98% | 0.17 | |
 SIGA | 336.57M | 4.70 | 14.24 | -31.8% | 24.64% | 0% | 0 | |
 CHRS | 212.02M | 1.75 | 1.22 | -84.2% | 398.43% | 7.89% | 0.02 | |
 GILD | 169.83B | 136.30 | 358.68 | 6.04% | 28.9% | 37.62% | 1.39 | |
 ABBV | 362.56B | 204.98 | 86.49 | 8.57% | 6.91% | 62.15% |
Compare VIR vs Peers
Vir Biotechnology, Inc. (VIR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VIR Income Statement
Vir Biotechnology, Inc. (VIR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 149K | 868K | 711K | 67.25M | 1.1B | 1.62B | 86.18M | 74.2M | 68.56M |
| Revenue Growth % | - | 482.55% | -18.09% | 9357.81% | 1528.99% | 47.51% | -94.67% | -13.9% | -7.61% |
| Cost of Goods Sold | 62.51M | 100.23M | 0 | 0 | 513.87M | 620.97M | 572.83M | 478.64M | 11.71M |
| COGS % of Revenue | 41954.36% | 11547.12% | - | - | 46.91% | 38.43% | 664.69% | 645.03% | 17.08% |
| Gross Profit | -62.36M▲ 0% | -99.36M▼ 59.3% | 711K▲ 100.7% | 67.25M▲ 9357.8% | 581.54M▲ 764.8% | 994.83M▲ 71.1% | -486.65M▼ 148.9% | -404.44M▲ 16.9% | 56.85M▲ 114.1% |
| Gross Margin % | -41854.36% | -11447.12% | 100% | 100% | 53.09% | 61.57% | -564.69% | -545.03% | 82.92% |
| Gross Profit Growth % | - | -59.33% | 100.72% | 9357.81% | 764.81% | 71.07% | -148.92% | 16.89% | 114.06% |
| Operating Expenses | 81.65M | 119.56M | 178.69M | 364.23M | 160.79M | 161.76M | 197.66M | 182.72M | 524.87M |
| OpEx % of Revenue | 54795.97% | 13774.19% | 25132.21% | 541.64% | 14.68% | 10.01% | 229.35% | 246.24% | 765.61% |
| Selling, General & Admin | 21.69M | 29.13M | 37.6M | 70.94M | 0 | 0 | 0 | 0 | 92.07M |
| SG&A % of Revenue | 14559.06% | 3356.11% | 5288.05% | 105.49% | - | - | - | - | 134.3% |
| Research & Development | 62.51M | 100.23M | 148.47M | 302.41M | 448.01M | 474.65M | 579.72M | 506.5M | 432.8M |
| R&D % of Revenue | 41954.36% | 11547.12% | 20882.14% | 449.72% | 40.9% | 29.38% | 672.69% | 682.57% | 631.3% |
| Other Operating Expenses | 83K | -212K | -7.38M | -9.12M | -287.21M | -312.89M | -382.06M | -323.77M | 0 |
| Operating Income | -81.5M▲ 0% | -118.69M▼ 45.6% | -177.98M▼ 50.0% | -296.98M▼ 66.9% | 420.75M▲ 241.7% | 833.07M▲ 98.0% | -684.3M▼ 182.1% | -587.16M▲ 14.2% | -468.02M▲ 20.3% |
| Operating Margin % | -54695.97% | -13674.19% | -25032.21% | -441.64% | 38.41% | 51.56% | -794.04% | -791.27% | -682.68% |
| Operating Income Growth % | - | -45.64% | -49.95% | -66.86% | 241.68% | 98% | -182.14% | 14.2% | 20.29% |
| EBITDA | -81.06M | -115.94M | -173.46M | -291.54M | 426.56M | 839.85M | -664.85M | -572.61M | -456.34M |
| EBITDA Margin % | -54406.04% | -13356.68% | -24396.91% | -433.55% | 38.94% | 51.98% | -771.47% | -771.65% | -665.65% |
| EBITDA Growth % | - | -43.02% | -49.62% | -68.07% | 246.31% | 96.89% | -179.16% | 13.87% | 20.3% |
| D&A (Non-Cash Add-back) | 432K | 2.76M | 4.52M | 5.44M | 5.81M | 6.78M | 19.45M | 14.56M | 11.68M |
| EBIT | -81.5M | -118.69M | -177.98M | -296.98M | 420.75M | 833.07M | -661.09M | -523.47M | -437.77M |
| Net Interest Income | 638K | 2.54M | 8.51M | 2.84M | 439K | 28.09M | 86.99M | 71.81M | 40.24M |
| Interest Income | 638K | 2.54M | 8.51M | 2.84M | 439K | 28.09M | 86.99M | 71.81M | 40.24M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 721K | 2.33M | 3.45M | -1.63M | 129.05M | -78.79M | 56.11M | 64.06M | 30.25M |
| Pretax Income | -80.78M▲ 0% | -116.36M▼ 44.1% | -174.53M▼ 50.0% | -298.61M▼ 71.1% | 549.8M▲ 284.1% | 754.28M▲ 37.2% | -628.19M▼ 183.3% | -523.11M▲ 16.7% | -437.77M▲ 16.3% |
| Pretax Margin % | -54212.08% | -13405.99% | -24546.98% | -444.06% | 50.19% | 46.68% | -728.93% | -704.95% | -638.56% |
| Income Tax | -10.92M | -480K | 154K | 54K | 21.22M | 238.44M | -13.08M | -1.15M | 217K |
| Effective Tax Rate % | 13.52% | 0.41% | -0.09% | -0.02% | 3.86% | 31.61% | 2.08% | 0.22% | -0.05% |
| Net Income | -69.85M▲ 0% | -115.88M▼ 65.9% | -174.68M▼ 50.7% | -298.67M▼ 71.0% | 528.58M▲ 277.0% | 515.84M▼ 2.4% | -615.06M▼ 219.2% | -521.96M▲ 15.1% | -437.99M▲ 16.1% |
| Net Margin % | -46880.54% | -13350.69% | -24568.64% | -444.14% | 48.25% | 31.92% | -713.69% | -703.4% | -638.87% |
| Net Income Growth % | - | -65.9% | -50.74% | -70.98% | 276.98% | -2.41% | -219.24% | 15.14% | 16.09% |
| Net Income (Continuing) | -69.85M | -115.88M | -174.68M | -298.67M | 528.58M | 515.84M | -615.12M | -521.96M | -437.99M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.02▲ 0% | -1.20▲ 88.0% | -1.62▼ 35.0% | -2.51▼ 54.9% | 3.96▲ 257.8% | 3.83▼ 3.3% | -4.59▼ 219.8% | -3.83▲ 16.6% | -3.16▲ 17.5% |
| EPS Growth % | - | 88.02% | -35% | -54.94% | 257.77% | -3.28% | -219.84% | 16.56% | 17.49% |
| EPS (Basic) | -10.02 | -1.20 | -1.62 | -2.51 | 4.07 | 3.89 | -4.59 | -3.83 | -3.16 |
| Diluted Shares Outstanding | 6.97M | 96.91M | 107.65M | 119.16M | 133.44M | 134.81M | 134.13M | 136.25M | 138.52M |
| Basic Shares Outstanding | 6.97M | 96.91M | 107.65M | 119.16M | 129.88M | 132.61M | 134.13M | 136.25M | 138.52M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
VIR Balance Sheet
Vir Biotechnology, Inc. (VIR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 192.35M | 117.78M | 403M | 772.37M | 1.56B | 2.52B | 1.59B | 1.04B | 514.08M |
| Cash & Short-Term Investments | 187.92M | 98.44M | 383.44M | 736.86M | 708.14M | 2.4B | 1.52B | 905.35M | 462.86M |
| Cash Only | 187.92M | 47.6M | 109.33M | 436.57M | 347.81M | 848.63M | 241.58M | 222.95M | 234.11M |
| Short-Term Investments | 0 | 50.84M | 274.1M | 300.29M | 360.33M | 1.55B | 1.28B | 682.4M | 228.75M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 773.08M | 0 | 0 | 0 | 3.6M |
| Days Sales Outstanding | - | - | - | - | 257.6 | - | - | - | 19.17 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 10.76M | 6.18M | 7.99M | 8.59M | 59.2M | 65.82M | 137.11M | 47.62M |
| Total Non-Current Assets | 59.22M | 73.81M | 109.04M | 146.4M | 391.45M | 283.01M | 330.83M | 356.33M | 488.74M |
| Property, Plant & Equipment | 5.14M | 12.29M | 16.31M | 79.89M | 130.05M | 188.17M | 167.2M | 122.86M | 117.72M |
| Fixed Asset Turnover | 0.03x | 0.07x | 0.04x | 0.84x | 8.42x | 8.59x | 0.52x | 0.60x | 0.58x |
| Goodwill | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M | 16.94M |
| Intangible Assets | 35.88M | 36.92M | 35.66M | 33.82M | 33.29M | 32.76M | 22.57M | 8.1M | 7.85M |
| Long-Term Investments | 1M | 7.67M | 24.29M | 0 | 201.39M | 23.93M | 105.28M | 190.01M | 314.57M |
| Other Non-Current Assets | 1.26M | 7.67M | 15.85M | 15.75M | 9.78M | -228.5M | 18.86M | 18.42M | 31.66M |
| Total Assets | 251.57M▲ 0% | 191.6M▼ 23.8% | 512.07M▲ 167.3% | 918.76M▲ 79.4% | 1.95B▲ 112.7% | 2.8B▲ 43.4% | 1.92B▼ 31.5% | 1.4B▼ 27.1% | 1B▼ 28.3% |
| Asset Turnover | 0.00x | 0.00x | 0.00x | 0.07x | 0.56x | 0.58x | 0.04x | 0.05x | 0.07x |
| Asset Growth % | - | -23.84% | 167.27% | 79.42% | 112.71% | 43.38% | -31.51% | -27.11% | -28.31% |
| Total Current Liabilities | 12.44M | 39.91M | 59.21M | 99.06M | 341.24M | 511.03M | 175.41M | 119.66M | 92.81M |
| Accounts Payable | 4.9M | 6.47M | 5.88M | 5.08M | 6.52M | 6.42M | 6.33M | 5.08M | 9.8M |
| Days Payables Outstanding | 28.6 | 23.57 | - | - | 4.63 | 3.77 | 4.04 | 3.87 | 305.66 |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8.8M |
| Deferred Revenue (Current) | 0 | 8.76M | 6.18M | 6.45M | 98.21M | 15.52M | 64.85M | 12.65M | 0 |
| Other Current Liabilities | 0 | 22.02M | 22.08M | 10.6M | 0 | 7.65M | 9.35M | 16.06M | 74.21M |
| Current Ratio | 15.46x | 2.95x | 6.81x | 7.80x | 4.58x | 4.93x | 9.05x | 8.71x | 5.54x |
| Quick Ratio | 15.46x | 2.95x | 6.81x | 7.80x | 4.58x | 4.93x | 9.05x | 8.71x | 5.54x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 308.04M | 330.87M | 28.92M | 102.84M | 181.18M | 213.1M | 153.42M | 128.77M | 144.73M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 89.05M |
| Capital Lease Obligations | 0 | 0 | 0 | 66.56M | 133.56M | 123.84M | 111.67M | 90.14M | 89.05M |
| Deferred Tax Liabilities | 3.31M | 3.31M | 3.31M | 3.25M | 18.44M | 3.25M | 0 | 0 | 0 |
| Other Non-Current Liabilities | 10.4M | 10.84M | 12.95M | 29.22M | 25.36M | 32.8M | 40.22M | 38.63M | -33.38M |
| Total Liabilities | 320.48M | 370.77M | 88.13M | 201.91M | 522.42M | 724.13M | 328.82M | 248.43M | 237.55M |
| Total Debt | 0 | 10.14M | 237K | 70.18M | 137.49M | 127.97M | 124.54M | 97.89M | 186.91M |
| Net Debt | -187.92M | -37.46M | -109.1M | -366.39M | -210.33M | -720.66M | -117.04M | -125.06M | -47.2M |
| Debt / Equity | - | - | 0.00x | 0.10x | 0.10x | 0.06x | 0.08x | 0.09x | 0.24x |
| Debt / EBITDA | - | - | - | - | 0.32x | 0.15x | - | - | - |
| Net Debt / EBITDA | - | - | - | - | -0.49x | -0.86x | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | -68.92M▲ 0% | -179.18M▼ 160.0% | 423.94M▲ 336.6% | 716.85M▲ 69.1% | 1.43B▲ 99.7% | 2.08B▲ 45.1% | 1.59B▼ 23.5% | 1.15B▼ 27.7% | 765.28M▼ 33.5% |
| Equity Growth % | - | -159.99% | 336.61% | 69.09% | 99.74% | 45.12% | -23.47% | -27.66% | -33.48% |
| Book Value per Share | -9.88 | -1.85 | 3.94 | 6.02 | 10.73 | 15.41 | 11.86 | 8.44 | 5.52 |
| Total Shareholders' Equity | -68.92M | -179.18M | 423.94M | 716.85M | 1.43B | 2.08B | 1.59B | 1.15B | 765.28M |
| Common Stock | 1K | 1K | 11K | 13K | 13K | 13K | 13K | 14K | 14K |
| Retained Earnings | -77.95M | -193.84M | -368.52M | -667.18M | -138.6M | 377.24M | -237.82M | -759.78M | -1.2B |
| Treasury Stock | 0 | -14.67M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -292.52M | -14K | -601K | -1.28M | -1.1M | -9.12M | -815K | -1.72M | -2.06M |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VIR Cash Flow Statement
Vir Biotechnology, Inc. (VIR) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -66.38M | -94.1M | -129.63M | -190.94M | -47.59M | 1.66B | -778.78M | -446.35M | -391.78M |
| Operating CF Margin % | -44551.01% | -10840.55% | -18232.35% | -283.95% | -4.34% | 102.94% | -903.67% | -601.51% | -571.48% |
| Operating CF Growth % | - | -41.75% | -37.77% | -47.29% | 75.08% | 3595.04% | -146.82% | 42.69% | 12.23% |
| Net Income | -69.85M | -115.88M | -174.68M | -298.67M | 528.58M | 515.84M | -615.06M | -521.96M | -437.99M |
| Depreciation & Amortization | 432K | 2.76M | 4.52M | 5.44M | 5.81M | 6.78M | 19.45M | 14.56M | 21.15M |
| Stock-Based Compensation | 4.78M | 5.05M | 8.72M | 27.6M | 83.78M | 102.08M | 0 | 78.46M | 49.07M |
| Deferred Taxes | -10.92M | -480K | 0 | -52K | 15.19M | -15.19M | -1.06M | -2.95M | 0 |
| Other Non-Cash Items | 4.32M | 1.97M | 23.61M | 45.21M | -52.56M | 388.37M | 122.48M | 69.55M | -1.57M |
| Working Capital Changes | 4.86M | 12.49M | 8.2M | 29.52M | -628.39M | 665.37M | -304.59M | -84.01M | -22.45M |
| Change in Receivables | 0 | 0 | 0 | 0 | -773.08M | 770.04M | -565K | -6.51M | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 52.81M | 0 | 0 | 0 | 0 |
| Change in Payables | 2.01M | 1.47M | 964K | -790K | -171K | 797K | 732K | -988K | 5M |
| Cash from Investing | -29.99M | -60.44M | -256.16M | -9.86M | -140.81M | -1.19B | 164.73M | 499.37M | 310.37M |
| Capital Expenditures | -2.74M | -8.19M | -8.94M | -6.55M | -21.82M | -68.01M | -21.57M | -7.3M | -4.83M |
| CapEx % of Revenue | 1840.27% | 943.78% | 1257.38% | 9.74% | 1.99% | 4.21% | 25.03% | 9.84% | 7.05% |
| Acquisitions | -27.25M | 25K | 0 | 0 | 140.81M | 0 | 100K | 3.37M | 253K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -1.74M | 0 | 180K | -140.81M | 0 | 0 | 0 | 0 |
| Cash from Financing | 271.18M | 24.98M | 449.24M | 529.47M | 100.33M | 34.76M | 7.38M | 4.39M | 3.79M |
| Debt Issued (Net) | 0 | 0 | 4.37M | -250K | -259K | -260K | -287K | -165K | -361K |
| Equity Issued (Net) | 271.18M | 24.39M | 443.74M | 529.91M | 85.21M | 28.46M | 7.77M | 4.55M | 4.15M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -3K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 584K | 1.13M | -189K | 15.38M | 6.56M | -100K | 0 | 0 |
| Net Change in Cash | 174.81M▲ 0% | -129.56M▼ 174.1% | 63.45M▲ 149.0% | 328.67M▲ 418.0% | -88.07M▼ 126.8% | 504.55M▲ 672.9% | -606.47M▼ 220.2% | 57.4M▲ 109.5% | -77.63M▼ 235.2% |
| Free Cash Flow | -69.12M▲ 0% | -102.29M▼ 48.0% | -138.57M▼ 35.5% | -197.49M▼ 42.5% | -69.41M▲ 64.9% | 1.6B▲ 2398.4% | -800.36M▼ 150.2% | -453.65M▲ 43.3% | -396.61M▲ 12.6% |
| FCF Margin % | -46391.28% | -11784.33% | -19489.73% | -293.69% | -6.34% | 98.73% | -928.71% | -611.35% | -578.52% |
| FCF Growth % | - | -47.98% | -35.47% | -42.52% | 64.86% | 2398.43% | -150.17% | 43.32% | 12.57% |
| FCF per Share | -9.91 | -1.06 | -1.29 | -1.66 | -0.52 | 11.83 | -5.97 | -3.33 | -2.86 |
| FCF Conversion (FCF/Net Income) | 0.95x | 0.81x | 0.74x | 0.64x | -0.09x | 3.22x | 1.27x | 0.86x | 0.89x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 252.03M | 0 | 786K | 0 |
VIR Key Ratios
Vir Biotechnology, Inc. (VIR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -142.74% | -52.36% | 49.2% | 29.39% | -33.53% | -38.09% | -45.73% |
| Return on Invested Capital (ROIC) | - | - | -271.84% | -66.96% | 40.15% | 48.46% | -36.26% | -35.25% | -40.27% |
| Gross Margin | -41854.36% | -11447.12% | 100% | 100% | 53.09% | 61.57% | -564.69% | -545.03% | 82.92% |
| Net Margin | -46880.54% | -13350.69% | -24568.64% | -444.14% | 48.25% | 31.92% | -713.69% | -703.4% | -638.87% |
| Debt / Equity | - | - | 0.00x | 0.10x | 0.10x | 0.06x | 0.08x | 0.09x | 0.24x |
| FCF Conversion | 0.95x | 0.81x | 0.74x | 0.64x | -0.09x | 3.22x | 1.27x | 0.86x | 0.89x |
| Revenue Growth | - | 482.55% | -18.09% | 9357.81% | 1528.99% | 47.51% | -94.67% | -13.9% | -7.61% |
VIR SEC Filings & Documents
Vir Biotechnology, Inc. (VIR) SEC filings — annual & quarterly reports (10-K, 10-Q)
VIR Frequently Asked Questions
Vir Biotechnology, Inc. (VIR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Vir Biotechnology, Inc. (VIR) reported $68.6M in revenue for fiscal year 2025. This represents a 45911% increase from $0.1M in 2017.
Vir Biotechnology, Inc. (VIR) saw revenue decline by 7.6% over the past year.
Vir Biotechnology, Inc. (VIR) reported a net loss of $438.0M for fiscal year 2025.
Dividend & Returns
Vir Biotechnology, Inc. (VIR) has a return on equity (ROE) of -45.7%. Negative ROE indicates the company is unprofitable.
Vir Biotechnology, Inc. (VIR) had negative free cash flow of $391.8M in fiscal year 2025, likely due to heavy capital investments.
Explore More VIR
Vir Biotechnology, Inc. (VIR) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates